Quantum Biopharma Ltd (QNTM) Stock Price, Quote & News

Company Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 571 1811

Website: www.quantumbiopharma.com

Address:

55 University Avenue, Suite 1003, Toronto, Canada

Ronin275 Nov. 8 at 11:00 PM

$QNTM $GNS https://x.com/zsaeed/status/1987292382132601314?s=46

0 · Reply

crystalfang Nov. 8 at 6:02 AM

$QNTM

0 · Reply

NoFearHere Nov. 7 at 9:26 PM

$QNTM looking like reversal wants to happen

0 · Reply

gloryb Nov. 7 at 3:14 PM

$QNTM criminals

0 · Reply

DonCorleone77 Nov. 7 at 12:08 PM

$QNTM Quantum BioPharma reports Q3 EPS ($1.25) vs. (4.37) last year -- Digital assets totaled $5.2M as of September 30, 2025, compared to $0.8M as of December 31, 2024.

0 · Reply

FifthWheelFrank Nov. 6 at 9:22 PM

$QNTM Kevin says he’s backing up the truck 🤣😂🤣

0 · Reply

StockOperator Nov. 6 at 7:48 PM

$QNTM LES GROan ⬇️⬇️⬇️

0 · Reply

SomeNothingBurgers Nov. 6 at 7:35 PM

$QNTM daaaamn. I’ve been on vacation. 🥴

0 · Reply

Wearewhowethought Nov. 6 at 2:35 PM

$GNS $QNTM $NVDA $GNS lawsuit filing 5 days liquidity crises squueze time $GME

0 · Reply

thirdeyeanalyst888 Nov. 6 at 2:31 PM

$QNTM Dilution is the Solution

0 · Reply

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Oct 31, 2025, 7:51 PM EDT - 8 days ago

Quantum BioPharma Ltd. Provides Corporate Update

Oct 29, 2025, 9:00 PM EDT - 10 days ago

Quantum BioPharma Ltd. Announces Corporate Updates

Oct 23, 2025, 8:15 AM EDT - 17 days ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

Oct 20, 2025, 8:30 AM EDT - 20 days ago

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Oct 14, 2025, 8:15 AM EDT - 26 days ago

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

Oct 9, 2025, 6:00 PM EDT - 4 weeks ago

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

Oct 9, 2025, 5:40 PM EDT - 4 weeks ago

QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm

Oct 8, 2025, 8:00 AM EDT - 4 weeks ago

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Oct 7, 2025, 11:00 AM EDT - 4 weeks ago

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

Oct 3, 2025, 7:00 AM EDT - 5 weeks ago

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

Oct 2, 2025, 7:57 AM EDT - 5 weeks ago

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

Oct 1, 2025, 7:50 AM EDT - 5 weeks ago

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

Sep 29, 2025, 7:40 AM EDT - 5 weeks ago

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Sep 26, 2025, 8:00 PM EDT - 6 weeks ago

Quantum BioPharma Announces Corporate Updates

Sep 24, 2025, 8:30 AM EDT - 6 weeks ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

Sep 18, 2025, 8:10 AM EDT - 7 weeks ago

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

Sep 12, 2025, 7:50 AM EDT - 2 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Sep 10, 2025, 7:00 AM EDT - 2 months ago

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target

Aug 11, 2025, 6:32 PM EDT - 3 months ago

Quantum BioPharma Announces Update to Previously Announced Private Placement

Aug 11, 2025, 7:40 AM EDT - 3 months ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

Aug 8, 2025, 8:00 AM EDT - 3 months ago

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Aug 7, 2025, 7:00 AM EDT - 3 months ago

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Aug 5, 2025, 7:34 AM EDT - 3 months ago

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

Aug 4, 2025, 7:33 AM EDT - 3 months ago

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

Jul 31, 2025, 7:24 AM EDT - 3 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO

Jul 30, 2025, 4:00 PM EDT - 3 months ago

Quantum BioPharma Shares' Rollercoaster Day: What's Going On?

Jul 22, 2025, 7:00 AM EDT - 3 months ago

Quantum BioPharma Makes Strategic Investment in GameStop Corp.

GME

Jun 27, 2025, 4:30 PM EDT - 4 months ago

Quantum BioPharma Announces Private Placement

Jun 26, 2025, 7:30 AM EDT - 4 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering

Jun 18, 2025, 9:19 AM EDT - 5 months ago

Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress

Jun 17, 2025, 8:00 AM EDT - 5 months ago

Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

Jun 13, 2025, 7:00 AM EDT - 5 months ago

Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds

Jun 3, 2025, 7:50 AM EDT - 5 months ago

Quantum BioPharma Clarifies It Has Not Changed Its Name

Jun 2, 2025, 1:47 PM EDT - 5 months ago

iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients

May 30, 2025, 7:00 AM EDT - 5 months ago

Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari

May 29, 2025, 7:30 AM EDT - 5 months ago

Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.

May 28, 2025, 8:00 AM EDT - 5 months ago

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

May 20, 2025, 7:30 AM EDT - 6 months ago

Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis

May 19, 2025, 7:30 AM EDT - 6 months ago

Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000

May 16, 2025, 7:30 AM EDT - 6 months ago

Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference

May 12, 2025, 8:00 AM EDT - 6 months ago

Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis

May 6, 2025, 8:25 PM EDT - 6 months ago

Quantum BioPharma Ltd. (QNTM) Business Update Conference Call Transcript

May 5, 2025, 7:08 AM EDT - 6 months ago

Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Apr 24, 2025, 7:00 AM EDT - 7 months ago

Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time

Apr 22, 2025, 7:00 AM EDT - 7 months ago

Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor

Apr 18, 2025, 8:00 PM EDT - 7 months ago

Quantum BioPharma Corporate Update

Apr 14, 2025, 7:30 AM EDT - 7 months ago

Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario

Apr 3, 2025, 7:00 AM EDT - 7 months ago

Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico

Apr 1, 2025, 2:00 AM EDT - 7 months ago

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis

Ronin275 Nov. 8 at 11:00 PM

$QNTM $GNS https://x.com/zsaeed/status/1987292382132601314?s=46

0 · Reply

crystalfang Nov. 8 at 6:02 AM

$QNTM

0 · Reply

NoFearHere Nov. 7 at 9:26 PM

$QNTM looking like reversal wants to happen

0 · Reply

gloryb Nov. 7 at 3:14 PM

$QNTM criminals

0 · Reply

DonCorleone77 Nov. 7 at 12:08 PM

$QNTM Quantum BioPharma reports Q3 EPS ($1.25) vs. (4.37) last year -- Digital assets totaled $5.2M as of September 30, 2025, compared to $0.8M as of December 31, 2024.

0 · Reply

FifthWheelFrank Nov. 6 at 9:22 PM

$QNTM Kevin says he’s backing up the truck 🤣😂🤣

0 · Reply

StockOperator Nov. 6 at 7:48 PM

$QNTM LES GROan ⬇️⬇️⬇️

0 · Reply

SomeNothingBurgers Nov. 6 at 7:35 PM

$QNTM daaaamn. I’ve been on vacation. 🥴

0 · Reply

Wearewhowethought Nov. 6 at 2:35 PM

$GNS $QNTM $NVDA $GNS lawsuit filing 5 days liquidity crises squueze time $GME

0 · Reply

thirdeyeanalyst888 Nov. 6 at 2:31 PM

$QNTM Dilution is the Solution

0 · Reply

Redman70 Nov. 5 at 8:53 PM

$QNTM Hey Zeeshan.....cancel the ATM. You should be able to already see that the volume has dried up quickly in your stock! No one wants to buy a stock that is currently in an ATM. Publicly announce the cancellation and try this instead -- finish something! Your unbuzzd drink has been sitting stagnant for months (will soon be "years."). You had plenty of cash after the last ATM (and didn't you guys say you wouldn't need to dilute until like 2027 or something??.....or did I dream that?!). You also have digital currencies in your coffers, correct? Sell those and use that cash. Quit paying yourself high salaries. Quit using company money to refinance your mortgage. These are all things that could help your market cap. Just my opinions of course.

1 · Reply

BriancPressRowe Nov. 5 at 12:13 PM

$GNS isn't Roger buddies with the CEO of $QNTM woof! Kill for that same pump but that CEO is a crook too

0 · Reply

linkansgar Nov. 5 at 7:36 AM

$QNTM I will buy a lot of shares here after $GNS fuks up shorts 🩳

1 · Reply

IncognitoBull Nov. 5 at 12:43 AM

$QNTM choke. Zeeshan finally diluted. Shocker

0 · Reply

Redman70 Nov. 4 at 9:05 PM

$QNTM Has anyone tried to call these nimrods to try to get some clarity on WHY they are doing another ATM? And why so much? And timing? And do they have anything at all in the near future that could give them a reason to only use the ATM at much higher prices? I can see a company filing for an ATM but not using it until a "catalyst" propels the price ---- but not sure if that's what these guys are doing here. Anyone have any thoughts?

1 · Reply

NoFearHere Nov. 4 at 8:10 PM

$QNTM 6.92 holds worth a bite if that fails 6.17+ 5.55+4.35 + Then ROCK BOTTOM 3.50🤯

0 · Reply

ShadowSnake Nov. 4 at 7:51 PM

$QNTM holy moly this was at $42 when Malone was around … 😳😳

0 · Reply

FifthWheelFrank Nov. 4 at 6:28 PM

$QNTM well we all knew an offering was coming. Somehow they have to pay for the $7 million reward 😂🤣 Kevin!!!

0 · Reply

Redman70 Nov. 4 at 5:00 PM

$QNTM So far, it looks like they aren't being too careful with the ATM. lol They def are scumbags.

1 · Reply

gloryb Nov. 4 at 4:51 PM

$QNTM scumbags, all of them

0 · Reply

Redman70 Nov. 4 at 4:43 PM

$QNTM Maybe they will be smarter this time around with the ATM. Maybe they won't just keep hitting the bid on the stock and they will actually have PR's and good news that will drive the stock up, while they only take small bits of the ATM out of daily volume. Maybe they'll use some of the money to purchase back a larger position in Unbuzzd, (if they believe that drink will ever be successful). There is currently a capital raise in process over there at Unbuzzd, so maybe some of the funds will be used for that. Who knows. But QNTM best start performing for the shareholders or there will be law firms at the gates more than likely. There were some pretty big promises made by their hired advisors that kept people in this stock as well as encouraged people to buy the stock. That's not good for QNTM (unless they fulfill those promises). These are just my opinions - not advice.

0 · Reply

gloryb Nov. 4 at 3:37 PM

$QNTM a big fat middle finger to retail 🖕

0 · Reply

Market Cap	34.00M
Revenue (ttm)	0.00
Net Income (ttm)	-14.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	40,900
Avg Vol	111,660
Day's Range	N/A - N/A
Shares Out	3.82M
Stochastic %K	15%
Beta	0.54
Analysts	Sell
Price Target	$35.50